These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
142 related articles for article (PubMed ID: 39390065)
1. DAA treatment for HCV reduce risk of hepatocellular carcinoma: a 10-years follow-up study based on Chinese patients with hepatitis C. Zhu X; Jia L; Yue M; Zhang A; Xia X; Yu R; Chen H; Huang P Sci Rep; 2024 Oct; 14(1):23760. PubMed ID: 39390065 [TBL] [Abstract][Full Text] [Related]
2. Incidence of Hepatocellular Carcinoma in Patients With HCV-Associated Cirrhosis Treated With Direct-Acting Antiviral Agents. Calvaruso V; Cabibbo G; Cacciola I; Petta S; Madonia S; Bellia A; Tinè F; Distefano M; Licata A; Giannitrapani L; Prestileo T; Mazzola G; Di Rosolini MA; Larocca L; Bertino G; Digiacomo A; Benanti F; Guarneri L; Averna A; Iacobello C; Magro A; Scalisi I; Cartabellotta F; Savalli F; Barbara M; Davì A; Russello M; Scifo G; Squadrito G; Cammà C; Raimondo G; Craxì A; Di Marco V; Gastroenterology; 2018 Aug; 155(2):411-421.e4. PubMed ID: 29655836 [TBL] [Abstract][Full Text] [Related]
3. Hepatocellular carcinoma, decompensation, and mortality based on hepatitis C treatment: A prospective cohort study. Choi GH; Jang ES; Kim YS; Lee YJ; Kim IH; Cho SB; Lee HC; Jang JW; Ki M; Choi HY; Baik D; Jeong SH World J Gastroenterol; 2022 Aug; 28(30):4182-4200. PubMed ID: 36157119 [TBL] [Abstract][Full Text] [Related]
4. Risk of Hepatocellular Cancer in HCV Patients Treated With Direct-Acting Antiviral Agents. Kanwal F; Kramer J; Asch SM; Chayanupatkul M; Cao Y; El-Serag HB Gastroenterology; 2017 Oct; 153(4):996-1005.e1. PubMed ID: 28642197 [TBL] [Abstract][Full Text] [Related]
5. Low incidence of HCC in chronic hepatitis C patients with pretreatment liver stiffness measurements below 17.5 kilopascal who achieve SVR following DAAs. Søholm J; Hansen JF; Mössner B; Røge BT; Lauersen A; Hansen JB; Weis N; Barfod TS; Lunding S; Øvrehus A; Mohey R; Thielsen P; Christensen PB PLoS One; 2020; 15(12):e0243725. PubMed ID: 33301499 [TBL] [Abstract][Full Text] [Related]
6. Sustained virologic response to direct-acting antiviral agents predicts better outcomes in hepatitis C virus-infected patients: A retrospective study. Colussi G; Donnini D; Brizzi RF; Maier S; Valenti L; Catena C; Cavarape A; Sechi LA; Soardo G World J Gastroenterol; 2019 Oct; 25(40):6094-6106. PubMed ID: 31686765 [TBL] [Abstract][Full Text] [Related]
7. Direct-acting antivirals after successful treatment of early hepatocellular carcinoma improve survival in HCV-cirrhotic patients. Cabibbo G; Celsa C; Calvaruso V; Petta S; Cacciola I; Cannavò MR; Madonia S; Rossi M; Magro B; Rini F; Distefano M; Larocca L; Prestileo T; Malizia G; Bertino G; Benanti F; Licata A; Scalisi I; Mazzola G; Di Rosolini MA; Alaimo G; Averna A; Cartabellotta F; Alessi N; Guastella S; Russello M; Scifo G; Squadrito G; Raimondo G; Trevisani F; Craxì A; Di Marco V; Cammà C; J Hepatol; 2019 Aug; 71(2):265-273. PubMed ID: 30959157 [TBL] [Abstract][Full Text] [Related]
8. Long-term effect of sustained virological response on hepatocellular carcinoma in patients with hepatitis C in Canada. Janjua NZ; Chong M; Kuo M; Woods R; Wong J; Yoshida EM; Sherman M; Butt ZA; Samji H; Cook D; Yu A; Alvarez M; Tyndall M; Krajden M J Hepatol; 2017 Mar; 66(3):504-513. PubMed ID: 27818234 [TBL] [Abstract][Full Text] [Related]
9. Reduction of the Risk of Hepatocellular Carcinoma over Time Using Direct-Acting Antivirals: A Propensity Score Analysis of a Real-Life Cohort (PITER HCV). Quaranta MG; Cavalletto L; Russo FP; Calvaruso V; Ferrigno L; Zanetto A; Mattioli B; D'Ambrosio R; Panetta V; Brancaccio G; Raimondo G; Brunetto MR; Zignego AL; Coppola C; Iannone A; Biliotti E; Rosselli Del Turco E; Massari M; Licata A; Barbaro F; Persico M; Morisco F; Pompili M; Cerini F; Puoti M; Santantonio T; Craxì A; Kondili LA; Chemello L; On Behalf Of Piter Collaborating Investigators Viruses; 2024 Apr; 16(5):. PubMed ID: 38793565 [TBL] [Abstract][Full Text] [Related]
10. Human Immunodeficiency Virus (HIV) Infection Is Associated With Lower Risk of Hepatocellular Carcinoma After Sustained Virological Response to Direct-acting Antivirals in Hepatitis C Infected Patients With Advanced Fibrosis. Corma-Gómez A; Macías J; Lacalle-Remigio JR; Téllez F; Morano L; Rivero A; Serrano M; Ríos MJ; Vera-Méndez FJ; Alados JC; Real LM; Palacios R; Santos IL; Imatz A; Pineda JA; Clin Infect Dis; 2021 Oct; 73(7):e2109-e2116. PubMed ID: 32766891 [TBL] [Abstract][Full Text] [Related]
11. Treatment with direct-acting antivirals for HCV decreases but does not eliminate the risk of hepatocellular carcinoma. Piñero F; Mendizabal M; Ridruejo E; Herz Wolff F; Ameigeiras B; Anders M; Schinoni MI; Reggiardo V; Palazzo A; Videla M; Alonso C; Santos L; Varón A; Figueroa S; Vistarini C; Adrover R; Fernández N; Perez D; Tanno F; Hernández N; Sixto M; Borzi S; Bruno A; Cocozzella D; Soza A; Descalzi V; Estepo C; Zerega A; de Araujo A; Cheinquer H; Silva M; Liver Int; 2019 Jun; 39(6):1033-1043. PubMed ID: 30636361 [TBL] [Abstract][Full Text] [Related]
12. Improved survival of patients with hepatocellular carcinoma and compensated hepatitis C virus-related cirrhosis who attained sustained virological response. Bruno S; Di Marco V; Iavarone M; Roffi L; Boccaccio V; Crosignani A; Cabibbo G; Rossi S; Calvaruso V; Aghemo A; Giacomelli L; Craxì A; Colombo M; Maisonneuve P Liver Int; 2017 Oct; 37(10):1526-1534. PubMed ID: 28418617 [TBL] [Abstract][Full Text] [Related]
13. The impact of treatment of hepatitis C with DAAs on the occurrence of HCC. Roche B; Coilly A; Duclos-Vallee JC; Samuel D Liver Int; 2018 Feb; 38 Suppl 1():139-145. PubMed ID: 29427487 [TBL] [Abstract][Full Text] [Related]
14. Increased Risk for Hepatocellular Carcinoma Persists Up to 10 Years After HCV Eradication in Patients With Baseline Cirrhosis or High FIB-4 Scores. Ioannou GN; Beste LA; Green PK; Singal AG; Tapper EB; Waljee AK; Sterling RK; Feld JJ; Kaplan DE; Taddei TH; Berry K Gastroenterology; 2019 Nov; 157(5):1264-1278.e4. PubMed ID: 31356807 [TBL] [Abstract][Full Text] [Related]
15. Sustained virological response to direct-acting antiviral regimens reduces the risk of hepatocellular carcinoma in HIV/HCV-coinfected patients with cirrhosis. Merchante N; Rivero-Juárez A; Téllez F; Merino D; Ríos-Villegas MJ; Villalobos M; Omar M; Rincón P; Rivero A; Pérez-Pérez M; Raffo M; López-Montesinos I; Palacios R; Gómez-Vidal MA; Macías J; Pineda JA; J Antimicrob Chemother; 2018 Sep; 73(9):2435-2443. PubMed ID: 29982683 [TBL] [Abstract][Full Text] [Related]
16. Hepatocellular Carcinoma Incidences and Risk Factors in Hepatitis C Patients: Interferon versus Direct-Acting Agents. Kao YT; Liu YC; Cheng YT; Wen YW; Hsieh YC; Hsu CE; Su CW; Tai JC; Chen YC; Jeng WJ; Lin CY; Chien RN; Tai DI; Sheen IS Viruses; 2024 Sep; 16(9):. PubMed ID: 39339961 [TBL] [Abstract][Full Text] [Related]
17. The association between hepatocellular carcinoma and direct-acting anti-viral treatment in patients with decompensated cirrhosis. Mecci AJ; Kemos P; Leen C; Lawson A; Richardson P; Khakoo SI; Agarwal K; Mutimer D; Rosenberg WM; Foster GR; Irving WL; Aliment Pharmacol Ther; 2019 Jul; 50(2):204-214. PubMed ID: 31149748 [TBL] [Abstract][Full Text] [Related]
18. Incidence of Hepatocellular Carcinoma After Direct Antiviral Therapy for HCV in Patients With Cirrhosis Included in Surveillance Programs. Nahon P; Layese R; Bourcier V; Cagnot C; Marcellin P; Guyader D; Pol S; Larrey D; De Lédinghen V; Ouzan D; Zoulim F; Roulot D; Tran A; Bronowicki JP; Zarski JP; Riachi G; Calès P; Péron JM; Alric L; Bourlière M; Mathurin P; Blanc JF; Abergel A; Serfaty L; Mallat A; Grangé JD; Attali P; Bacq Y; Wartelle C; Dao T; Thabut D; Pilette C; Silvain C; Christidis C; Nguyen-Khac E; Bernard-Chabert B; Zucman D; Di Martino V; Sutton A; Roudot-Thoraval F; Audureau E; Gastroenterology; 2018 Nov; 155(5):1436-1450.e6. PubMed ID: 30031138 [TBL] [Abstract][Full Text] [Related]
19. Systematic review with meta-analysis: effectiveness of direct-acting antiviral treatment for hepatitis C in patients with hepatocellular carcinoma. He S; Lockart I; Alavi M; Danta M; Hajarizadeh B; Dore GJ Aliment Pharmacol Ther; 2020 Jan; 51(1):34-52. PubMed ID: 31808566 [TBL] [Abstract][Full Text] [Related]
20. Risk of hepatocellular carcinoma occurrence after antiviral therapy for patients with chronic hepatitis C Infection: a systematic review and meta-analysis. Lv GJ; Ji D; Yu L; Chen HY; Chen J; He M; Wang WC; Wang HB; Tsang C; Wang J; Yu ML; Lau G; Hepatol Int; 2024 Oct; 18(5):1459-1471. PubMed ID: 38965190 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]